Vertex to buy Crinetics for $10 billion in rare-disease expansion

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash, paying a 102 percent premium to build an endocrinology franchise around the rare-disease drugmaker's pipeline.

Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for $10 billion in cash, or $85 a share, a 102 percent premium, adding the approved acromegaly drug Palsonify and a late-stage congenital adrenal hyperplasia candidate.

"Vertex can build on the strong momentum of the PALSONIFY launch by applying our experience in commercializing medicines for rare genetic diseases," Reshma Kewalramani, chief executive officer of Vertex, said in a statement.

The all-cash deal values Crinetics at about $8.8 billion net of estimated cash acquired. Vertex will finance the purchase with cash on hand and debt, backed by $4.5 billion of fully committed bridge financing from Bank of America and Morgan Stanley. Both boards approved the transaction, which is expected to close in the third quarter of 2026 subject to antitrust and shareholder approvals. Crinetics shares jumped nearly 99 percent in premarket trading, while Vertex shares dipped slightly.

The acquisition gives Vertex, best known for its cystic fibrosis franchise, a fifth commercial pillar in endocrinology. Analysts estimate the combined assets could generate peak annual sales above $5 billion, helping the company diversify beyond CF. Vertex shares trade around $522, up 15.5 percent year to date.

Palsonify and atumelnant anchor the deal

Crinetics' lead product Palsonify (paltusotine), an oral once-daily therapy, won European Commission approval in April for acromegaly, a rare hormonal disorder caused by excess growth hormone. The drug challenges injectable somatostatin analogs from Novartis and Ipsen that dominate the market. Vertex plans to apply its rare-disease commercial infrastructure to expand Palsonify's reach in the U.S. and other markets.

The second asset, atumelnant, is in Phase III trials for congenital adrenal hyperplasia, a genetic condition that impairs cortisol production. Vertex said the candidate could set a new standard of care by reducing the trade-off between controlling excess adrenal androgens and enduring the side effects of high-dose steroids.

Financing and deal terms

Morgan Stanley and Lazard advised Vertex, while J.P. Morgan Securities and Leerink Partners advised Crinetics. The agreement includes a $350.5 million termination fee payable by Crinetics if the deal falls through. Vertex expects the transaction to become accretive to non-GAAP operating income in 2029.

The deal is among the largest biopharma transactions of the year, part of a busy July that also saw Eli Lilly agree to acquire AtaiBeckley for up to $3.8 billion and Johnson & Johnson secure a $2.58 billion option on Sail Biomedicines. For Vertex, the purchase extends a push beyond its core CF business, which generated about $12 billion in 2025 revenue, into pain with JOURNAVX and gene editing with CASGEVY. For Crinetics shareholders, the 102 percent premium caps a run that saw the stock climb after Palsonify's approval. The key question for Vertex investors is whether the $10 billion price tag justifies the eventual contribution to revenue and adjusted operating income management targets by 2029.

This article is for informational purposes only and does not constitute investment advice.